- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- December 2023
- 200 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 120 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- October 2022
- 216 Pages
Middle East
From €2030EUR$2,100USD£1,744GBP
€2900EUR$3,000USD£2,491GBP
- Report
- December 2021
- 191 Pages
Global
From €3079EUR$3,185USD£2,645GBP
€4399EUR$4,550USD£3,778GBP
- Report
- August 2022
- 100 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- May 2020
- 200 Pages
Global
From €6719EUR$6,950USD£5,771GBP
- Report
- July 2018
- 30 Pages
China
From €2127EUR$2,200USD£1,827GBP
- Drug Pipelines
- September 2020
- 35 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- February 2024
- 87 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- August 2022
- 87 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- May 2022
- 40 Pages
Global
From €1934EUR$2,000USD£1,661GBP
Enoxaparin is a cardiovascular drug used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a low molecular weight heparin (LMWH) that works by preventing the formation of blood clots. Enoxaparin is administered by subcutaneous injection and is available in both generic and branded forms. It is often used in combination with other anticoagulants such as warfarin. Enoxaparin is also used to reduce the risk of stroke and heart attack in patients with acute coronary syndrome.
Enoxaparin is a widely used drug in the cardiovascular market and is available in many countries around the world. It is often prescribed as a first-line treatment for DVT and PE, and is also used in the prevention and treatment of other cardiovascular conditions.
Some companies in the Enoxaparin market include Sanofi, Pfizer, Bristol-Myers Squibb, and GlaxoSmithKline. Show Less Read more
